ClinicalTrials.gg
CompletedNCT04024137Updated Jun 4, 2020

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

A Phase 2 interventional study of ZSP1273 200 mg and Placebo in Influenza A, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 26 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Enrollment
110th of 157
172 · median 360
Started
2019
with 8 others
Phase 2
16 of 173
1 open now
Registered
83rd of 173
by date
Lead sponsor
5 of 173
Guangdong Raynovent Biotech Co., Ltd

Among the 173 studies in Influenza, Human with a site in China, this one is the 110th largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2019, is one of 16 in phase 2, and was the 83rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the antiviral effect, as measured by the time to alleviation of influenza symptoms and viral titer in nasopharyngeal secretions in adults with acute uncomplicated influenza A following administration of ZSP1273.

03

Conditions studied

  • Influenza A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and female subjects between 18-65 years (Both inclusive).
  2. Patients with a diagnosis of influenza virus A infection confirmed by all of the following:

    • Positive Rapid Antigen Test (RAT) with throat swabs;and
    • Fever≥38.0ºC (axillary) in the predose examinations;and
    • At least one of the following general systemic symptoms and respiratory symptoms respectively associated with influenza are present with a severity of moderate or greater:

      • General systemic symptoms:Headache,Feverishness or chills,Muscle or joint pain,Fatigue;
      • Respiratory symptoms:Cough,Sore throat,Nasal congestion.
  3. The time interval between the onset of symptoms and the enrollment is≤48 hours. The onset of symptoms is defined as:

    • Time of the first increase in body temperature(axillary temperature≥38.0ºC),or
    • Time when the patient experiences at least one general or respiratory symptom.
  4. Subjects who agree to use an appropriate method of during the study and up to 6 months after drug withdrawal.
  5. Signature of a dated Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Known and/or allergy to some drugs and food,especially for the composition that is similar to ZSP1273;
  2. Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs.
  3. Use of the following medications within 7 days prior to screening:

    • Influenza antiviral medication:oseltamivir,peramivir,famivir,abidol,amantadine or rimantadine.
    • Chinese patent medicine or herbal medicine with antiviral effect.
  4. Patients who have received influenza vaccine within 6 months prior to enrollment.
  5. Presence of abnormalities in .
  6. Chest X - ray examination confirmed bronchitis,pneumonia,pleural effusion or pulmonary interstitial lesions.
  7. Patients who have experienced respiratory tract infection,Otitis media,nasosinusitis.
  8. White blood cells(WBC)>10.0×109/L at screening.
  9. Subject who produces purulent sputum or has suppurative tonsillitis.
  10. Patients with severe or uncontrollable underlying diseases:blood disorders,severe (COPD),liver disorders( or AST≥3 ,total ≥1.5 ULN),kidney disorders(serum creatinine>177μmol/L or 2mg/dL),chronic congestive heart failure( III-IV),mental disorders.
  11. Immunodeficiency,including malignant tumor,organ or marrow transplant, [HIV] infection,or patients receiving therapy 3 months prior to enrollment.
  12. Concomitant therapy with aspirin or salicylic acid.
  13. Morbid obesity( [BMI]≥30kg/m2).
  14. Known history of alcohol abuse or drug abuse.
  15. Pregnancy or breastfeeding at screening and during the study.All female subjects of must have a negative urine pregnancy test at screening and during the trial.
  16. Have received any other products within 3 months prior to dosing.
  17. Subjects who should not be included in the study in the opinion of the Investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    ZSP1273-200 mg BID

    Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.

    Drug: ZSP1273 200 mg · Drug: Placebo

  • Experimental
    ZSP1273-400 mg BID

    Subjects will receive 10 doses of ZSP1273 400mg(200mg\*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.

    Drug: ZSP1273-400 mg · Drug: Placebo

  • Experimental
    ZSP1273-600 mg QD

    Subjects will receive 5 doses of ZSP1273 600mg (200mg \*3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .

    Drug: ZSP1273-600 mg · Drug: Placebo

  • Placebo comparator
    Placebo

    Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.

    Drug: Placebo

Interventions

  • 1 X 200-mg tablet taken orally

  • DrugPlacebo

    2 tablets taken orally

  • 2 X 200-mg tablet taken orally

  • DrugPlacebo

    1 tablet taken orally

  • 3 X 200-mg tablet taken orally

  • DrugPlacebo

    3 tablets taken orally

  • DrugPlacebo

    Subjects will receive matching placebo of ZSP1273

06

What researchers measure

Primary outcomes

  1. Time to alleviation of influenza symptoms in participants

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all 7 influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours

    Time frame: Initiation of study treatment (Day 1) up to Day 15

Secondary outcomes

  1. AUC of the log10 pharyngeal viral load

    Area under the curve (AUC) of the log10 pharyngeal viral load is measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).

    Time frame: Days 6

  2. Change in the total score of 7 influenza symptoms

    Participants assessed the severity of seven influenza-associated symptoms(cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms(Sum of symptom scores) as assessed by the participant, and ranges from 0 to 21.

    Time frame: Up to Day15

  3. Time to alleviation of each influenza symptom.

    Participants assessed the severity of seven influenza-associated symptoms(cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.

    Time frame: Up to Day15

  4. Time to Resolution of Fever

    Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours.

    Time frame: Up to Day15

  5. Proportion of patients reporting normal temperature

    Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.

    Time frame: Up to Day15

  6. Percentage of subjects with virus titer detected

    Influenza virus RNA was quantified from throat swabs.Proportion of patients positive for influenza virus titer is defined as the percentage of patients whose virus titer is not less than the lower limit of quantification among those assessed for virus titer measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) on Days 2,4, 6.

    Time frame: Days 2,4, 6

  7. Duration of detectable virus

    Defined as the time from the start of treatment to the time when the titer is less than the lower limit of quantification measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).

    Time frame: Days 2,4, 6

  8. Change in virus titer

    Defined as the change from baseline in virus titer measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).

    Time frame: Days 2,4, 6

  9. Change in viral RNA load

    Defined as the change from baseline in viral RNA load measured by viral culture and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) on Days 2, 4, 6.

    Time frame: Days 2,4, 6

  10. Incidence of influenza-related complications

    Defined as the percentage of subjects in the analysis population who experience each influenza-related complication (sinusitis, otitis media, bronchitis, and pneumonia) as an adverse event after the initiation of the study treatment.

    Time frame: Up to Day21

  11. Time to return to normal activities of daily life

    Participants were asked to record their activities of daily life on a scale from 0 (worst possible health) to 10 (normal activities of daily life). Time to return to normal activities of daily life defined as the time between the initiation of the study treatment and the return to normal activities of daily life. The return to normal activities of daily life is defined as the time when the subject assesses his/her activities as 10.Subjects with a baseline self-rated daily activity score of 10 are not included in this analysis.

    Time frame: Up to Day15

  12. Proportion of patients with the Serological conversion of neutralizing antibody titer relative to that in Visit 1 ≥4

    Defined as the protprtion of patients with a ratio of 4 or more at Visit 5 antibody titer relative to Visit 1 titer

    Time frame: Baseline and Day 21

  13. Proportion of patients and frequency in combination use of acetaminophen.

    The proportion of patients who use acetaminophen in the duration of the study

    Time frame: Up to 21 days post-dose

  14. Change in EQ-5D-5L

    Defined as the change from baseline in the index value and that in EQ VAS score as calculated from the EQ-5D-5L questionnaire.

    Time frame: Baseline up to Day 15

07

Study locations

26 sites
  • The Second Hospital Of Anhui Medical University
    Hefei, Anhui, China
  • Beijing Ditan Hospital Capital Medical University
    Beijing, Beijing, China
  • Beijing Luhe Hospital,Capital Medical University
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian, China
  • Dongguan people's Hospital
    Dongguan, Guangdong, China
  • Nanfang Hospital,South Medical Hospital
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital Of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Traditional Chinese Medicine Hospital of Guangdong Province
    Guangzhou, Guangdong, China
  • Huizhou Municipal Central Hospital
    Huizhou, Guangdong, China
  • Jieyang People's Hospital
    Jieyang, Guangdong, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • Affiliated Hospital Of Guangdong Medical University
    Zhanjiang, Guangdong, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
  • The Sixth People's Hospital Of Zhengzhou
    Zhengzhou, Henan, China
  • Sir Run Run Hospital Nanjing Medical University
    Nanjing, Jiangsu, China
  • Jiujiang University Hospital
    Jiujiang, Jiangxi, China
  • The First Affiliated Hospital Of Nanchang University
    Nanchang, Jiangxi, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • Linyi People's Hospital
    Linyi, Shandong, China
  • Qingdao Municipal Hospital
    Qingdao, Shandong, China
  • First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Chengdu Fifth People's Hospital
    Chengdu, Sichuan, China
  • General Hospital, Tianjin Medical University
    Tianjin, Tianjin, China
  • The First Affiliated Hospital,Zhejiang University
    Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in May 2020, 5 months.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 5 months is below that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2019
First posted
Jul 18, 2019
StartActual
Dec 7, 2019
Primary completionActual
May 18, 2020
CompletionActual
May 18, 2020
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04024137
Responsible party
Sponsor
First posted
Jul 18, 2019
Start date
Dec 7, 2019
Primary completion
May 18, 2020
Completion
May 18, 2020
Last update
Jun 4, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZSP1273

Start the discussion